NEJM:万古霉素诱导的线性IgA大疱性皮肤病-病例报道

2020-10-15 MedSci原创 MedSci原创

该患者疑似为由万古霉素诱导的线性IgA大疱性皮肤病,并且终止了万古霉素治疗,同时继续使用头孢吡肟。该患者停用万古霉素治疗后1天,病变没有进一步发展。

患者为一名67岁的男子,因弥漫性皮疹1天而到急诊就诊。他有接受过放射疗法治疗的前列腺癌病史,并因尿道狭窄的发展而变得复杂,为此他接受了手术治疗。最近他又诊断有多发性耻骨骨髓炎和肌炎,开始用头孢吡肟和万古霉素治疗。抗生素治疗开始十天后,他注意到舌头有灼热感,随后红斑迅速发展,腹部、手臂和腿部出现水泡。

体格检查发现腋窝(如图A所示)和舌头(如图B所示)上有囊泡,腹部、手臂和腿上有囊泡的红斑,无发烧、嗜酸性粒细胞增多或器官功能障碍。活检标本的组织病理学检查发现有嗜中性乳头炎伴微泡(如图C所示,HE染色)。直接免疫荧光显示,IgA沿基底膜区线性沉积(如图D所示)。

该患者疑似为由万古霉素诱导的线性IgA大疱性皮肤病,并且终止了万古霉素治疗,同时继续使用头孢吡肟。该患者停用万古霉素治疗后1天,病变没有进一步发展。

在随访1个月时,该患者的粘膜皮肤病变完全消失。

原始出处:

J. Raymond Go,et al.Vancomycin-Induced Linear IgA Bullous Dermatosis.N Engl J Med 2020;https://www.nejm.org/doi/full/10.1056/NEJMicm2003334

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826143, encodeId=0450182614315, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 15 19:11:30 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976054, encodeId=5ec49e6054b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4c05531862, createdName=ms4000001557735858, createdTime=Wed Jun 23 09:09:55 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503955, encodeId=c2861503955de, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri Oct 16 23:11:30 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892332, encodeId=841189233281, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e85397868, createdName=ms7000000169409063, createdTime=Thu Oct 15 21:52:59 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035454, encodeId=a9eb1035454f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 15 11:11:30 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826143, encodeId=0450182614315, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 15 19:11:30 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976054, encodeId=5ec49e6054b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4c05531862, createdName=ms4000001557735858, createdTime=Wed Jun 23 09:09:55 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503955, encodeId=c2861503955de, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri Oct 16 23:11:30 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892332, encodeId=841189233281, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e85397868, createdName=ms7000000169409063, createdTime=Thu Oct 15 21:52:59 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035454, encodeId=a9eb1035454f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 15 11:11:30 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
    2021-06-23 ms4000001557735858

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1826143, encodeId=0450182614315, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 15 19:11:30 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976054, encodeId=5ec49e6054b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4c05531862, createdName=ms4000001557735858, createdTime=Wed Jun 23 09:09:55 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503955, encodeId=c2861503955de, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri Oct 16 23:11:30 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892332, encodeId=841189233281, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e85397868, createdName=ms7000000169409063, createdTime=Thu Oct 15 21:52:59 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035454, encodeId=a9eb1035454f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 15 11:11:30 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
    2020-10-16 yibei
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826143, encodeId=0450182614315, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 15 19:11:30 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976054, encodeId=5ec49e6054b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4c05531862, createdName=ms4000001557735858, createdTime=Wed Jun 23 09:09:55 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503955, encodeId=c2861503955de, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri Oct 16 23:11:30 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892332, encodeId=841189233281, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e85397868, createdName=ms7000000169409063, createdTime=Thu Oct 15 21:52:59 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035454, encodeId=a9eb1035454f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 15 11:11:30 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
    2020-10-15 ms7000000169409063

    涨知识

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1826143, encodeId=0450182614315, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 15 19:11:30 CST 2021, time=2021-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=976054, encodeId=5ec49e6054b9, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4c05531862, createdName=ms4000001557735858, createdTime=Wed Jun 23 09:09:55 CST 2021, time=2021-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1503955, encodeId=c2861503955de, content=<a href='/topic/show?id=641d94e7eb' target=_blank style='color:#2F92EE;'>#IgA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9477, encryptionId=641d94e7eb, topicName=IgA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c23f9697922, createdName=yibei, createdTime=Fri Oct 16 23:11:30 CST 2020, time=2020-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=892332, encodeId=841189233281, content=涨知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0e85397868, createdName=ms7000000169409063, createdTime=Thu Oct 15 21:52:59 CST 2020, time=2020-10-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035454, encodeId=a9eb1035454f9, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Oct 15 11:11:30 CST 2020, time=2020-10-15, status=1, ipAttribution=)]
    2020-10-15 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

JAMA:万古霉素联合抗葡萄球菌β-内酰胺类抗生素治疗MRSA菌血症

研究发现,对于耐甲氧西林金黄色葡萄球菌菌血症患者,在标准治疗方案中添加抗葡萄球菌β-内酰胺类抗生素不会改善患者死亡率

J Infect Dis:艰难梭菌感染首次复发的治疗:菲达索米星VS万古霉素

在成功治疗的患者中,约有25%的患者发生艰难梭菌感染(CDI)复发。研究人员在美国、加拿大和欧洲的154个地点进行了两项3期随机双盲试验,比较菲达索米星与万古霉素治疗CDI的效果

ARCH PATHOL LAB MED:庆大霉素和万古霉素对c8000临床化学参数的影响

庆大霉素和万古霉素是肾毒性抗生素,然而,目前对他们药物浓度对临床化学检测结果的影响知之甚少。本研究的目的是探讨庆大霉素和万古霉素对33项常用生化检测结果的干扰。 这项研究是在Sestre Milosrdnice(克罗地亚萨格勒布)大学化学系、医学院进行的。对于每种药物,均制备10份混合血清。为了覆盖毒性浓度,血清样本与药物混合以获得0到50μg /毫升的庆大霉素和0到200μg /毫升的万古

PLoS One:长期使用万古霉素具有低风险的耳毒性

万古霉素是一种常见的抗生素,具有有效的抗革兰氏阳性微生物活性,但是长时间和高剂量的使用能够导致耳毒性。虽然与万古霉素相关的肾毒性具有广泛的报道,耳毒性的案例却很少见到。最近,有研究人员确定了接受长期静脉内注射(IV)万古霉素患者听觉敏度图的不良变化发生情况,并鉴定了那些需要进行听力监测的高风险患者。研究对424名患者进行了筛选;92名患者在使用万古霉素期间至少进行了2次听力测定。53%的患者为男性

抗击艰难梭菌:“粘性抗生素”或可有效减少万古霉素的丢失

伪膜性结肠炎(PE)是由于感染艰难梭菌(有时还会感染金黄色葡萄球菌)而引起的结肠衰弱性炎症。口服万古霉素可以有效杀灭艰难梭菌。为了有效发挥作用,万古霉素必须留在胃肠道中,并且不能被稀释或通过肠壁进入血液而丢失。

Gastroenterology:粪便微生物菌群移植治疗复发性难治性梭状芽孢杆菌感染的疗效优于菲达霉素

粪便微生物群移植(FMT)被推荐用于治疗复发性艰难梭菌感染(rCDI)。我们进行了一项单中心随机试验,以比较FMT与非达霉素和万古霉素的疗效。